Danaher (NYSE:DHR) had its price objective hoisted by investment analysts at UBS Group from $158.00 to $165.00 in a report issued on Monday, BenzingaRatingsTable reports. The firm currently has a “buy” rating on the conglomerate’s stock. UBS Group’s price objective would suggest a potential upside of 12.48% from the stock’s previous close.
A number of other analysts have also issued reports on the company. Stifel Nicolaus reiterated a “hold” rating and issued a $150.00 price target on shares of Danaher in a report on Thursday, November 14th. Wolfe Research set a $154.00 price objective on Danaher and gave the stock a “buy” rating in a report on Friday, October 25th. Needham & Company LLC decreased their target price on Danaher from $155.00 to $152.00 and set a “buy” rating for the company in a research report on Monday, October 28th. ValuEngine lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $151.00 target price on shares of Danaher in a report on Monday, October 14th. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $147.53.
Shares of DHR opened at $146.69 on Monday. The firm has a market capitalization of $104.85 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.45 and a beta of 0.92. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.43 and a quick ratio of 3.09. Danaher has a 1-year low of $94.59 and a 1-year high of $147.33. The company has a 50-day moving average of $139.57 and a 200 day moving average of $139.66.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, October 24th. The conglomerate reported $1.16 EPS for the quarter, topping the Zacks’ consensus estimate of $1.15 by $0.01. The business had revenue of $5.04 billion for the quarter, compared to the consensus estimate of $5.02 billion. Danaher had a net margin of 12.13% and a return on equity of 11.42%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.10 EPS. On average, equities analysts anticipate that Danaher will post 4.76 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Howe & Rusling Inc. raised its position in shares of Danaher by 116.3% in the 3rd quarter. Howe & Rusling Inc. now owns 186 shares of the conglomerate’s stock worth $27,000 after acquiring an additional 100 shares in the last quarter. Next Capital Management LLC bought a new position in Danaher in the second quarter worth about $31,000. Litman Gregory Asset Management LLC bought a new position in Danaher in the second quarter worth about $33,000. Altshuler Shaham Ltd lifted its position in shares of Danaher by 59.3% during the second quarter. Altshuler Shaham Ltd now owns 239 shares of the conglomerate’s stock valued at $34,000 after buying an additional 89 shares during the last quarter. Finally, Pinnacle Bank lifted its position in shares of Danaher by 52.3% during the third quarter. Pinnacle Bank now owns 262 shares of the conglomerate’s stock valued at $38,000 after buying an additional 90 shares during the last quarter. 78.10% of the stock is currently owned by institutional investors.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: The Structure of a Futures Contract
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.